Professional Documents
Culture Documents
Contact address: Andrew J Carlin, Maternal Fetal Medicine Unit, John Hunter Hospital, Lookout Road, New
Lambton Heights, New South Wales, 2305,
Australia.andrew.carlin@hnehealth.nsw.gov.au. carlinandrew@doctors.org.uk.
Citation: Carlin AJ, Alfirevic Z, Gyte GML. Interventions for treating peripartum cardiomyopathy to improve
outcomes for women and babies. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008589.
DOI: 10.1002/14651858.CD008589.pub2.
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abstract
Background
Peripartum cardiomyopathy (PPCM or PCMO) is a rare disease of unknown
etiology, characterised by an acute onset of heart failure in women in the late stage
of pregnancy or in the early months postpartum.
Objectives
To assess the effectiveness and safety of any intervention for the care of women
and/or their babies with a diagnosis of peripartum cardiomyopathy.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (27
July 2010) and the reference lists of identified studies.
Selection criteria
Randomised and quasi-randomised controlled trials of any intervention for treating
peripartum cardiomyopathy. Such interventions include: drugs; cardiac monitoring
and treatment; haemodynamic monitoring and treatments; supportive therapies and
heart transplant.
Main results
We identified and included one pilot study, involving 20 women, undertaken in
South Africa. Women were diagnosed postnatally and included in the study within
24 hours of diagnosis.
Authors' conclusions
There are insufficient data to draw any firm conclusions. Treatment with
bromocriptine appears promising, although women would be unable to breastfeed
due to suppression of lactation.